Compare iShares MSCI Germany (DAX) (EWG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Viatris Inc — how do they compare? iShares MSCI Germany (DAX) trades at $40.97 (market cap $1.42B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 14.1× iShares MSCI Germany (DAX)'s market cap, and Viatris Inc pays a 2.75% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 54 Days and Viatris Inc for 57 Days on average.
| EWG | VTRS | |
|---|---|---|
Market Cap | $1.42B | $20.03B |
Volume | 1,110,573 | 14,109,977 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $18.27 |
52-Week Low | $38.08 | $9.74 |
Typical Hold Time | 54 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.
Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
